Advanced glycation end products promote osteoporosis by inducing ferroptosis in osteoblasts

Ge,Weiwei; Jie,Jian; Yao,Jie; Li,Wei; Cheng,Yahui; Lu,Wenjuan

doi:10.3892/mmr.2022.12656

Advanced glycation end products promote osteoporosis by inducing ferroptosis in osteoblasts

Authors:
- Weiwei Ge
- Jian Jie
- Jie Yao
- Wei Li
- Yahui Cheng
- Wenjuan Lu
View Affiliations

Affiliations: Department of Radiology, Pukou Branch of Jiangsu People's Hospital (Nanjing Pukou District Central Hospital), Nanjing, Jiangsu 210018, P.R. China, Department of Orthopedics, Pukou Branch of Jiangsu People's Hospital (Nanjing Pukou District Central Hospital), Nanjing, Jiangsu 210018, P.R. China, Department of Radiology, Nanjing Central Hospital (Nanjing Municipal Government Hospital), Nanjing, Jiangsu 210018, P.R. China
Published online on: February 24, 2022 https://doi.org/10.3892/mmr.2022.12656
Article Number: 140
Copyright: © Ge et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advanced glycation end products (AGEs) have been widely reported to play an important role in osteoporosis (OP), particularly in diabetes‑related OP. The aim of the present study was to investigate the effect of AGEs on osteoblast function and the underlying mechanisms. The level of bone mineral density (BMD), serum AGEs and fasting blood glucose (FBG) was measured in patients with OP and healthy individuals, and the correlation between AGE levels and BMD or FBG was then analyzed. For the in vitro experiments, the hFOB1.19 osteoblast cell line was cultured in medium containing AGEs and serum from healthy individuals or patients with OP, and with or without type‑2 diabetes mellitus (T2DM). Cell proliferation, differentiation, mineralization, apoptosis and ferroptosis were evaluated using Cell Counting Kit‑8 and alkaline phosphatase (ALP) assays, Alizarin red and TUNEL staining, iron indicator, lipid peroxidation tests and western blot analysis, respectively. In a separate set of experiments, the ferroptosis inhibitor, deferoxamine (DFO), was also added to the culture medium of cells treated with AGEs and serum from patients with OP and T2DM. The results demonstrated that patients with OP had a higher level of serum AGEs and FBG compared with that in healthy individuals. The level of serum AGEs in patients with OP was negatively correlated with BMD, but was positively correlated with FBG. In addition, AGEs and serum from patients with OP markedly inhibited hFOB1.19 cell proliferation, ALP production and mineralized nodule formation. Apoptosis and ferroptosis were significantly promoted by AGEs and serum from patients with OP. Moreover, serum from OP patients with T2DM caused stronger effect than that from OP patients with normal FBG. However, DFO reversed the effects induced by AGEs and serum from patients with OP and T2DM on hFOB1.19 cells. Collectively, AGEs could disrupt the functions of osteoblasts by inducing cell ferroptosis, thus contributing to OP.

View Figures

View References

1	Baccaro LF, Conde DM, Costa-Paiva L and Pinto-Neto AM: The epidemiology and management of postmenopausal osteoporosis: A viewpoint from Brazil. Clin Interv Aging. 10:583–591. 2015. View Article : Google Scholar : PubMed/NCBI
2	Armas LA and Recker RR: Pathophysiology of osteoporosis: New mechanistic insights. Endocrinol Metab Clin North Am. 41:475–486. 2012. View Article : Google Scholar : PubMed/NCBI
3	Reid IR: A broader strategy for osteoporosis interventions. Nat Rev Endocrinol. 16:333–339. 2020. View Article : Google Scholar : PubMed/NCBI
4	Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA, Tracy JK, Hochberg MC, Rodondi N and Cawthon PM; Study of Osteoporotic Fractures Research Group, : Frailty and risk of falls, fracture, and mortality in older women: The study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci. 62:744–751. 2007. View Article : Google Scholar : PubMed/NCBI
5	Johnston CB and Dagar M: Osteoporosis in older adults. Med Clin North Am. 104:873–884. 2020. View Article : Google Scholar : PubMed/NCBI
6	Kurra S, Fink DA and Siris ES: Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin North Am. 43:233–243. 2014. View Article : Google Scholar : PubMed/NCBI
7	Nowotny K, Jung T, Höhn A, Weber D and Grune T: Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 5:194–222. 2015. View Article : Google Scholar : PubMed/NCBI
8	Goh SY and Cooper ME: Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 93:1143–1152. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yamamoto M and Sugimoto T: Advanced glycation end products, diabetes, and bone strength. Curr Osteoporos Rep. 14:320–326. 2016. View Article : Google Scholar : PubMed/NCBI
10	Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L and Graves DT: Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 40:345–353. 2007. View Article : Google Scholar : PubMed/NCBI
11	Notsu M, Yamaguchi T, Okazaki K, Tanaka K, Ogawa N, Kanazawa I and Sugimoto T: Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion. Endocrinology. 155:2402–2410. 2014. View Article : Google Scholar : PubMed/NCBI
12	Meng HZ, Zhang WL, Liu F and Yang MW: Advanced glycation end products affect osteoblast proliferation and function by modulating autophagy via the receptor of advanced glycation end Products/Raf Protein/Mitogen-activated protein Kinase/Extracellular Signal-regulated Kinase Kinase/Extracellular Signal-regulated Kinase (RAGE/Raf/MEK/ERK) pathway. J Biol Chem. 290:28189–28199. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ma H, Wang X, Zhang W, Li H, Zhao W, Sun J and Yang M: Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoporosis. Oxid Med Cell Longev. 2020:90676102020. View Article : Google Scholar : PubMed/NCBI
14	Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G and Tang D: Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 66:89–100. 2020. View Article : Google Scholar : PubMed/NCBI
15	Lu J, Yang J, Zheng Y, Chen X and Fang S: Extracellular vesicles from endothelial progenitor cells prevent steroid-induced osteoporosis by suppressing the ferroptotic pathway in mouse osteoblasts based on bioinformatics evidence. Sci Rep. 9:161302019. View Article : Google Scholar : PubMed/NCBI
16	Xia D, Wu J, Xing M, Wang Y, Zhang H, Xia Y, Zhou P and Xu S: Iron overload threatens the growth of osteoblast cells via inhibiting the PI3K/AKT/FOXO3a/DUSP14 signaling pathway. J Cell Physiol. Jan 29–2019.(Epub ahead of print). doi: 10.1002/jcp.28217. View Article : Google Scholar
17	Wang X, Ma H, Sun J, Zheng T, Zhao P, Li H and Yang M: Mitochondrial ferritin deficiency promotes osteoblastic ferroptosis via mitophagy in type 2 diabetic osteoporosis. Biol Trace Elem Res. 200:298–307. 2022. View Article : Google Scholar : PubMed/NCBI
18	Tsukushi S, Katsuzaki T, Aoyama I, Takayama F, Miyazaki T, Shimokata K and Niwa T: Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: Role of the polyol pathway. Kidney Int. 55:1970–1976. 1999. View Article : Google Scholar : PubMed/NCBI
19	Kim HJ and Kim SG: Alterations in cellular Ca(2+) and free iron pool by sulfur amino acid deprivation: The role of ferritin light chain down-regulation in prooxidant production. Biochem Pharmacol. 63:647–657. 2002. View Article : Google Scholar : PubMed/NCBI
20	Sun Y, Zheng Y, Wang C and Liu Y: Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. Cell Death Dis. 9:7532018. View Article : Google Scholar : PubMed/NCBI
21	Cheng YZ, Yang SL, Wang JY, Ye M, Zhuo XY, Wang LT, Chen H, Zhang H and Yang L: Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sci. 205:184–192. 2018. View Article : Google Scholar : PubMed/NCBI
22	Sanguineti R, Puddu A, Mach F, Montecucco F and Viviani GL: Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm. 2014:9758722014. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Wang L, Zhang M, Huang K, Yao Z, Rao P, Cai X and Xiao J: Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt/β-catenin signalling pathway via DNA methylation. Cell Prolif. 53:e128342020. View Article : Google Scholar : PubMed/NCBI
24	de Paula FJ, Horowitz MC and Rosen CJ: Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev. 26:622–630. 2010. View Article : Google Scholar : PubMed/NCBI
25	Saito M, Fujii K, Mori Y and Marumo K: Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 17:1514–1523. 2006. View Article : Google Scholar : PubMed/NCBI
26	Yang DH, Chiang TI, Chang IC, Lin FH, Wei CC and Cheng YW: Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis. Int J Med Sci. 11:453–460. 2014. View Article : Google Scholar : PubMed/NCBI
27	Lee WC, Guntur AR, Long F and Rosen CJ: Energy metabolism of the osteoblast: Implications for osteoporosis. Endocr Rev. 38:255–266. 2017. View Article : Google Scholar : PubMed/NCBI
28	Sanguineti R, Storace D, Monacelli F, Federici A and Odetti P: Pentosidine effects on human osteoblasts in vitro. Ann NY Acad Sci. 1126:166–172. 2008. View Article : Google Scholar : PubMed/NCBI
29	Franke S, Rüster C, Pester J, Hofmann G, Oelzner P and Wolf G: Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol. 29:650–660. 2011.PubMed/NCBI
30	Lee EJ, Kang MK, Kim YH, Kim DY, Oh H, Kim SI, Oh SY, Na W and Kang YH: Coumarin ameliorates impaired bone turnover by inhibiting the formation of advanced glycation end products in diabetic osteoblasts and osteoclasts. Biomolecules. 10:10522020. View Article : Google Scholar : PubMed/NCBI
31	Dariya B and Nagaraju GP: Advanced glycation end products in diabetes, cancer and phytochemical therapy. Drug Discov Today. 25:1614–1623. 2020. View Article : Google Scholar : PubMed/NCBI
32	Ni S, Yuan Y, Qian Z, Zhong Z, Lv T, Kuang Y and Yu B: Hypoxia inhibits RANKL-induced ferritinophagy and protects osteoclasts from ferroptosis. Free Radic Biol Med. 169:271–282. 2021. View Article : Google Scholar : PubMed/NCBI
33	Casati L, Pagani F, Fibiani M, Lo Scalzo R and Sibilia V: Potential of delphinidin-3-rutinoside extracted from Solanum melongena L. as promoter of osteoblastic MC3T3-E1 function and antagonist of oxidative damage. Eur J Nutr. 58:1019–1032. 2019. View Article : Google Scholar : PubMed/NCBI
34	Hirschhorn T and Stockwell BR: The development of the concept of ferroptosis. Free Radic Biol Med. 133:130–143. 2019. View Article : Google Scholar : PubMed/NCBI
35	Mirlohi MS, Yaghooti H, Shirali S, Aminasnafi A and Olapour S: Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major. Ann Hematol. 97:679–684. 2018. View Article : Google Scholar : PubMed/NCBI
36	Chen SH, Yuan KC, Lee YC, Shih CK, Tseng SH, Tinkov AA, Skalny AV and Chang JS: Iron and advanced glycation end products: Emerging role of Iron in androgen deficiency in obesity. Antioxidants (Basel). 9:2612020. View Article : Google Scholar : PubMed/NCBI
37	He M, Siow RC, Sugden D, Gao L, Cheng X and Mann GE: Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: A role for Nrf2 in vascular protection in diabetes. Nutr Metab Cardiovasc Dis. 21:277–285. 2011.PubMed/NCBI
38	Ko SY, Chang SS, Lin IH and Chen HI: Suppression of antioxidant Nrf-2 and downstream pathway in H9c2 cells by advanced glycation end products (AGEs) via ERK phosphorylation. Biochimie. 118:8–14. 2015. View Article : Google Scholar : PubMed/NCBI
39	Suttner DM and Dennery PA: Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J. 13:1800–1809. 1999. View Article : Google Scholar : PubMed/NCBI
40	Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W and Wang J: Molecular mechanisms of ferroptosis and its role in cancer therapy. J Cell Mol Med. 23:4900–4912. 2019. View Article : Google Scholar : PubMed/NCBI